相关实验视频
Updated: May 24, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
944
雷米布鲁丁尼布用于慢性自发性疹
Martin Metz1,2, Ana Giménez-Arnau3, Michihiro Hide4,5
1Urticaria Center of Reference and Excellence, Institute of Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin.
The New England journal of medicine
|March 5, 2025
概括
在3期试验中,雷米布鲁丁尼在慢性自发性疹患者中显著降低了和疹. 这种口服布鲁顿的氨酸激酶抑制剂显示了持续的疗效和与安慰剂相似的安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性自发性疹 (CSU) 的特点是持续超过六周的反复,疹或血管.
- 雷米布鲁丁尼布是一种口服布鲁顿的氨酸激酶抑制剂,此前在CSU的2b期试验中显示出积极的结果.
- 来自第三阶段试验的进一步数据是必要的,以确认雷米布鲁丁尼布的疗效和安全性.
研究的目的:
- 评估雷米布鲁丁尼布在患有症状慢性自发性疹症的患者的疗效和安全性.
- 评估雷米布鲁丁尼布对疹活动得分的影响,包括和疹.
- 为了比较雷米布鲁丁尼布与安慰剂的有效性,在那些对抗胰岛素药物没有充分反应的患者中.
主要方法:
- 进行了相同的,多中心的,双盲的,随机的,安慰剂控制的REMIX-1和REMIX-2试验.
- 患者接受口服雷米布鲁丁尼布 (25毫克每天两次) 或安慰剂以2:1的比例.
- 主要终点是从基线到第12周的7天疹活动评分 (UAS7) 的变化.
主要成果:
- 在这两项试验中,雷米布鲁丁尼布在第12周的UAS7显著减少,与安慰剂相比 (P<0.001).
- 与安慰剂相比,在接受雷米布鲁丁尼布的患者中,更高比例的患者在第12周达到6或更低的UAS7和0的UAS7.
- 两组之间不良事件的发生率相似,雷米布鲁丁尼布组中患上疹的频率更高 (3.8%对比0.3%).
结论:
- 在第12周,口服雷米布鲁丁尼比显著改善了疹症状,特别是和疹.
- 这项研究证实了雷米布鲁丁尼布在治疗慢性自发性疹症的有效性和可接受的安全性.
- 这些发现支持雷米布鲁丁尼作为CSU耐抗胰岛素耐药患者的潜在治疗选择.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
230
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
230
Drugs for Treatment of Diarrhea-Predominant IBS
139
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
139
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126

